ARDX — Ardelyx, Inc.

Summary of Ardelyx Q1 2026 Earnings Call

1. Key Financial Results and Metrics

• Total Product Revenues: $93.4 million, up 38% year-over-year from $67.8 million.
• IBSRELA Revenue: $70.1 million, a 58% increase compared to Q1 2025.
• XPHOZAH Revenue: $23.3 million, consistent with the prior year when adjusted for a favorable product return adjustment in Q1 2025.
• Net Loss: $37.6 million, or $0.15 per share, improved from a net loss of $41.1 million, or $0.17 per share, in Q1 2025.
• R&D Expenses: Increased to $20.2 million from $14.9 million, reflecting investment in the ACCEL Phase III trial.
• SG&A Expenses: Rose to $102.3 million from $83.2 million, driven by commercialization efforts.
• Cash Position: $238.1 million in cash, cash equivalents, and short-term investments.

2. Strategic Updates and Business Highlights

• IBSRELA Growth: Achieved significant year-over-year growth due to effective commercial strategies targeting IBS-C patients. The company aims for IBSRELA to reach at least $1 billion in annual revenue by 2029.
• XPHOZAH: Continued growth in demand with a focus on patient access, despite a challenging overall prescription market.
• Pipeline Development: Initiated the ACCEL trial for IBSRELA in chronic idiopathic constipation (CIC), with rapid site activation and patient recruitment.
• Pediatric Program: Ongoing studies for IBSRELA in pediatric patients, which could extend patent life by an additional six months.
• Leadership Changes: New appointments in the executive team, enhancing the company's capabilities.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Reiterated for IBSRELA between $410 million and $430 million, and for XPHOZAH between $110 million and $120 million.
• Long-Term Growth: IBSRELA projected to achieve a compound annual growth rate (CAGR) of 38% to reach $1 billion by 2029.
• Operational Expenses: Expected to remain around $520 million for the year, with a focus on balancing growth investments and cash flow positivity.

4. Bad News, Challenges, or Points of Concern

• Seasonality Impact: Q1 performance was affected by seasonal dynamics and severe winter storms, which temporarily disrupted growth.
• XPHOZAH Revenue Stability: While XPHOZAH revenue remained consistent, it was noted that the previous year's figures included a favorable adjustment that may not recur.
• Increased Expenses: Rising R&D and SG&A expenses could pressure profitability in the short term.
• Competitive Pressures: Potential competition from other therapies for IBS-C and CIC could impact market share and growth projections.

5. Notable Q&A Insights

• Demand Trends: Executives expressed confidence in continued demand growth for IBSRELA, despite seasonal fluctuations and external disruptions.
• Enrollment in ACCEL Trial: Enrollment is on track, with enthusiasm from both clinicians and patients, reflecting lessons learned from previous trials.
• Specialty Pharmacy Strategy: The IBSRELA Pharmacy Network is improving fulfillment and refill rates, which is crucial for driving growth.
• Market Dynamics: The company is cautious about the competitive landscape but believes that IBSRELA's unique positioning will sustain its growth trajectory.

Overall, Ardelyx demonstrated strong financial performance in Q1 2026, with significant growth in IBSRELA revenue and a clear strategy for future expansion, despite some challenges and competitive pressures.